Compare STDN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STDN | GENB |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2026 | 2026 |
| Metric | STDN | GENB |
|---|---|---|
| Price | $12.48 | $12.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $17.56 | ★ $27.00 |
| AVG Volume (30 Days) | 439.1K | ★ 1.1M |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $439.23 | N/A |
| Revenue Next Year | $259.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.05 | $11.00 |
| 52 Week High | $17.34 | $22.67 |
| Indicator | STDN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 32.99 |
| Support Level | $11.46 | $11.82 |
| Resistance Level | $13.73 | $13.96 |
| Average True Range (ATR) | 0.95 | 0.83 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 27.52 | 0.25 |
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.